


GENOMICS

JAK2 Testing Platform and Reporting Changes

Date issued: May 27, 2021

Effective April 12, 2021, the JAK2 V617F mutation detection assay, previously performed using the Qiagen ipsogen JAK2 RGQ PCR kit was moved from the Cobas Z480 instrument to the Qiagen Rotor-Gene Q as the latter instrument has superior analytical sensitivity (0.042% vs 0.01%). The Sensitivity and Methodology sections of the final report were updated to reflect this change. An additional LIS reporting comment was also created.

The following JAK2 reporting algorithm and comment(s) are to be used when reporting JAK2 assays:



References/Resources:

JAK 2 RCQ PCR Kit Handbook, Ref 673613, Qiagen GmbH

More Information:

https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/ipsogen-leukemia/ipsogen-jak2-rgq-pcr-kit-pma-us/

https://www.qiagen.com/us/products/discovery-and-translational-research/epigenetics/dnamethylation/methylation-specific-pcr/rotor-gene-g/?clear=true#orderinginformation

Contact Information:

Dr. Paul Park, Associate Medical Director of Genomics, 204-787-2998, ppark@sharedhealthmb.ca